Linotroban is a synthetic chemical compound primarily recognized for its role as a selective antagonist of the thromboxane A2 receptor. It is characterized by its potential therapeutic applications, particularly in the treatment of cardiovascular diseases due to its ability to inhibit platelet aggregation and vasoconstriction. The compound exhibits a unique molecular structure that contributes to its biological activity, and it is often studied for its pharmacological properties. Linotroban's mechanism of action involves blocking the effects of thromboxane A2, a potent vasoconstrictor and platelet aggregator, thereby promoting vasodilation and improving blood flow. Additionally, it has been investigated for its anti-inflammatory effects. As with many pharmaceuticals, the safety profile, dosage, and specific interactions with other medications are critical considerations in its use. Overall, Linotroban represents a significant area of research in the field of cardiovascular pharmacotherapy, with ongoing studies aimed at elucidating its full therapeutic potential and mechanisms of action.

Linotroban

120824-08-0: Linotroban [INN],  [(5-{2-[(phenylsulfonyl)amino]ethyl}thiophen-2-yl)oxy]acetic acid,  UNII-6O2O36OL57,  ((5-(2-Benzenesulfonamidoethyl)-2-thienyl)oxy)acetic acid

Linotroban(CL-871502) is a potent selective thromboxane (TXA2) receptor antagonist with antithrombotic activity.

CAS 120824-08-0: Linotroban

Linotroban

Ref: 54-BUP00958

Linotroban

Ref: TM-T25741